Jennifer Tjon

Hematologist/Associate Professor

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jennifer Tjon is an Associate Professor at Leiden University Medical Center in the Netherlands. Her research encompasses hematology with a focus on immune-mediated aplastic anemia, stem cell transplantation, and the impact of immune cell dynamics on patient outcomes. Recent publications highlight her work on the pathogenesis of immune-mediated conditions, quality of life in aplastic anemia patients, and the safety and efficacy of treatments such as SARS-CoV-2 vaccination in this population.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (4)

Rafael de la Camara

- Head of Haematology

Hospital Universitario Virgen del Rocío

SPAIN

View details

Erfan Nur

NETHERLANDS

View details

Mirjam H.M. Heemskerk

Associate professor, Head of Laboratory of experimental hematology

Leiden University Medical Center

NETHERLANDS

View details

Marieke Ijsselsteijn

Leiden University Medical Center

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jennifer Tjon

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Imaging mass cytometry reveals the order of events in the pathogenesis of immune-mediated aplastic anemia

Haematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: an EBMT Inborn Errors Working Party study

The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.

Quality of life after immune suppressive therapy in aplastic anemia.

Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.

SARS‐CoV‐2 mRNA vaccination of aplastic anemia patients is safe and effective

SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria.

Mass cytometric analysis unveils a disease-specific immune cell network in the bone marrow in acquired aplastic anemia.

Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion.

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.

Collaborators (4)

Rafael de la Camara

Erfan Nur

Mirjam H.M. Heemskerk

Marieke Ijsselsteijn

Make your next move.